Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial

Journal:

Clinical Infectious Diseases

Published:

2026-05-17

DOI:

10.1093/cid/ciag315

Affiliations:

16

Authors:

18

Go to article

Institutions	Authors	Share
The Aurum Institute, South Africa	7.000000	0.39
University of the Witwatersrand, Johannesburg (Wits University), South Africa	2.000000	0.11
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom (UK)	1.333333	0.07
Vanderbilt University (VU), United States of America (USA)	1.000000	0.06
The Ohio State University (OSU), United States of America (USA)	1.000000	0.06
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.06
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.06
Center for Health Research Manhica (CISM), Mozambique	0.833333	0.05
Amsterdam Institute for Global Health and Development (AIGHD), Netherlands	0.500000	0.03
KNCV Tuberculosis Foundation, Netherlands	0.500000	0.03
National Institute for Public Health and the Environment (RIVM), VWS, Netherlands	0.500000	0.03
Barcelona Institute for Global Health (ISGlobal), Spain	0.333333	0.02
Biomedical Research Networking Center for Infectious Diseases (CIBERINFEC), Spain	0.333333	0.02
Africa Health Research Institute, South Africa	0.333333	0.02
University of KwaZulu-Natal (UKZN), South Africa	0.333333	0.02

Interested in Pharmacology and Pharmaceutical Sciences?